Clinical Trial: A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjogren's Disease

U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07737743) titled 'A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjogren's Disease' on July 27.

Brief Summary: To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjogren's disease (SjD) and to determine the dose response relationship of DDY391 in participants with SjD, to support dose selection for Phase 3.

Study Start Date: Aug. 27

Study Type: INTERVENTIONAL

Condition: Sjogren's Disease

Intervention: DRUG: DDY391

DDY391 dose level 1

DDY391 dose level 2

DDY391 dose level 3

DRUG: Placebo

Matching Placebo

Recruitment Status: NOT_YET_RECRUITING

Spon...